Human iPSCs were genetically engineered to generate isogenic cells carrying the AD-associated TREM2 R47H mutation, followed by in vitro differentiation and transplantation of HPCs into the 5x-hCSF1 or 5x-MITRG mouse models of AD and analysis 7 or 9 months after cell injection, respectively (Hasselmann et al., 2019; Claes et al., 2021). This evidence concerns the gene TREM2 and Alzheimer disease.